Rice Hall James & Associates LLC Has $14.37 Million Stock Position in NuVasive, Inc. (NASDAQ:NUVA)

Rice Hall James & Associates LLC increased its holdings in shares of NuVasive, Inc. (NASDAQ:NUVA) by 11.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 245,519 shares of the medical device company’s stock after buying an additional 24,340 shares during the quarter. Rice Hall James & Associates LLC owned 0.47% of NuVasive worth $14,373,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Geode Capital Management LLC lifted its position in shares of NuVasive by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 584,788 shares of the medical device company’s stock worth $28,981,000 after buying an additional 40,600 shares during the last quarter. Sector Gamma AS lifted its position in shares of NuVasive by 13.7% during the 1st quarter. Sector Gamma AS now owns 538,625 shares of the medical device company’s stock worth $30,589,000 after buying an additional 64,702 shares during the last quarter. Vaughan Nelson Investment Management L.P. lifted its position in shares of NuVasive by 23.2% during the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 391,625 shares of the medical device company’s stock worth $22,241,000 after buying an additional 73,760 shares during the last quarter. Rhumbline Advisers lifted its position in shares of NuVasive by 1.4% during the 1st quarter. Rhumbline Advisers now owns 165,863 shares of the medical device company’s stock worth $9,419,000 after buying an additional 2,303 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its position in shares of NuVasive by 2.0% during the 1st quarter. Gamco Investors INC. ET AL now owns 163,012 shares of the medical device company’s stock worth $9,257,000 after buying an additional 3,165 shares during the last quarter.

Shares of NUVA traded down $0.56 during mid-day trading on Thursday, reaching $63.07. 2,568 shares of the company were exchanged, compared to its average volume of 470,353. NuVasive, Inc. has a 52 week low of $43.51 and a 52 week high of $72.41. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.60 and a quick ratio of 1.99. The company has a market capitalization of $3.40 billion, a PE ratio of 28.30, a PEG ratio of 2.21 and a beta of 1.14. The stock has a 50 day simple moving average of $60.14.

NuVasive (NASDAQ:NUVA) last released its earnings results on Tuesday, July 30th. The medical device company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.56 by $0.07. NuVasive had a return on equity of 15.09% and a net margin of 4.65%. The business had revenue of $292.11 million during the quarter, compared to analysts’ expectations of $290.59 million. During the same quarter last year, the firm posted $0.58 earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. Equities research analysts predict that NuVasive, Inc. will post 2.32 EPS for the current fiscal year.

Several equities analysts have commented on NUVA shares. Cantor Fitzgerald reiterated a “hold” rating and issued a $61.00 target price on shares of NuVasive in a research report on Thursday, May 2nd. BMO Capital Markets increased their target price on NuVasive from $54.00 to $68.00 and gave the company a “market perform” rating in a research report on Friday, August 9th. ValuEngine upgraded NuVasive from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. TheStreet upgraded NuVasive from a “c+” rating to a “b” rating in a research report on Wednesday, July 31st. Finally, Morgan Stanley increased their target price on NuVasive from $57.00 to $67.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. NuVasive currently has an average rating of “Hold” and an average price target of $66.21.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

See Also: Asset Allocation, Balancing Your Investments

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.